ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE

Clinical Pharmacology Subcommittee

November 17 – 18, 2003

Rockville, MD

Bibliography

1. Wang, J., M. Neuvonen, X. Wen, J. Backman and P. Neuvonen.

Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism

in Human Liver Microsomes. Drug, Metabolism and Disposition

2002. DMD 30:1352-1356

2. Niemi, M., J.T. Backman, M. Neuvonen, P.J. Neuvonen. Effects of

gemfibrozil, itraconazole, and their combination on the

pharmacokinetics and pharmacodynamics of repagelinide:

potentially hazardous interaction between gemfibrozil and

repaglinide. Diabetologia 2003. 46:347-351

3. Backman, J.T., C. Kyrklund, M. Neuvonen and P. Neuvonen.

Gemfibrozil greatly increases plasma concentrations of Cerivastatin. Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital. American Society for Clinical Pharmacology and Therapeutics. 2002

4. Niemi, M., J.T. Backman, M. Granfors, J. Laitila, M. Neuvonen,

P.J. Neuvonen. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003. 46:1319-1323

5. Wen, X., J. Wang, J.T. Backman, J Laitila, and P. Neuvonen.

Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively. Drug, Metabolism and Disposition 2002. DMD 30:631-635

6. Ward, B., J. Gorski, D. Jones, S. Hall, D. Flockhart, and Z. Desta.

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalyst Activity. The Journal of Pharmacology and Experimental Therapeutics. 3/28/2003. JPET 306:287-300